Department of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
Pediatr Infect Dis J. 2013 Sep;32 Suppl 1(Suppl 1 Innovative Treatment Regimens for Severe Infections in Young Infants):S19-25. doi: 10.1097/INF.0b013e31829ff7aa.
Infection in young infants is a major cause of morbidity and mortality in low-middle income countries, with high neonatal mortality rates. Timely case management is lifesaving, but the current standard of hospitalization for parenteral antibiotic therapy is not always feasible. Alternative, simpler antibiotic regimens that could be used in outpatient settings have the potential to save thousands of lives.
This trial aims to determine whether 2 simplified antibiotic regimens are equivalent to the reference therapy with 7 days of once-daily (OD) intramuscular (IM) procaine penicillin and gentamicin for outpatient management of young infants with clinically presumed systemic bacterial infection treated in primary health-care clinics in 5 communities in Karachi, Pakistan. The reference regimen is close to the current recommendation of the hospital-based intravenous ampicillin and gentamicin therapy for neonatal sepsis. The 2 comparison arms are (1) IM gentamicin OD and oral amoxicillin twice daily for 7 days; and (2) IM penicillin and gentamicin OD for 2 days, followed by oral amoxicillin twice daily for 5 days; 2250 "evaluable" infants will be enrolled. The primary outcome of this trial is treatment failure (death, deterioration or lack of improvement) within 7 days of enrollment. Results are expected by early 2014.
This trial will determine whether simplified antibiotic regimens with fewer injections in combination with high-dose amoxicillin are equivalent to 7 days of IM procaine penicillin and gentamicin in young infants with clinical severe infection. Results will have program and policy implications in countries with limited access to hospital care and high burden of neonatal deaths.
在中低收入国家,婴儿感染是导致发病率和死亡率的主要原因,且新生儿死亡率较高。及时进行病例管理可拯救生命,但目前并非总是可行的对所有感染婴儿进行住院接受静脉注射抗生素治疗。在门诊环境下使用替代的、更简单的抗生素方案可能会拯救数千人的生命。
本试验旨在确定两种简化的抗生素方案是否与参考疗法等效,参考疗法为在巴基斯坦卡拉奇的 5 个社区的基层医疗诊所中,对疑似患有全身细菌感染的年轻婴儿进行门诊治疗,使用的方案为每天一次(OD)肌内(IM)普鲁卡因青霉素和庆大霉素,共 7 天。参考疗法接近目前基于医院的静脉注射氨苄青霉素和庆大霉素治疗新生儿败血症的建议。两种比较方案为:(1)OD 肌内注射庆大霉素和每天两次口服阿莫西林,共 7 天;(2)IM 青霉素和庆大霉素 OD 治疗 2 天,随后每天两次口服阿莫西林,共 5 天;将招募 2250 名“可评估”婴儿。本试验的主要结局是在登记后 7 天内治疗失败(死亡、病情恶化或无改善)。结果预计在 2014 年初得出。
本试验将确定在患有临床严重感染的婴儿中,使用注射次数较少的简化抗生素方案联合高剂量阿莫西林,是否与 IM 普鲁卡因青霉素和庆大霉素治疗等效。在可获得医院治疗机会有限且新生儿死亡负担较高的国家,该试验结果将具有项目和政策意义。